论文部分内容阅读
报告了作者自己制备复方白介素-2、干扰素及LAK细胞的方法,且采用~3H-TdR释放法对LAK细胞的杀伤率进行了测定(靶细胞为Hela、Hep-2、K_(562)3种传代肿瘤细胞)。结果表明:杀伤率为40～70％,应用LAK/IL-2CO治疗恶性肿瘤41例(共用LAK细胞239人次),发生副反应者19人次(发生率为7.9％)。提示异体LAK细胞是安全可行的。单用免疫制剂组有2例达到PR,另3例症状改善。免疫制剂配合化疗、放疗组有效率为54.1％。我们认为该疗法是目前综合治疗恶性肿瘤病人的一种副作用小、且安全、有效的方法,值得进一步探讨。
The authors reported their own methods of preparing compound interleukin-2, interferon and LAK cells, and measured the killing rate of LAK cells using ~3H-TdR release method (target cells were Hela, Hep-2, K562)3. Passage of tumor cells). The results showed that the killing rate was 40-70%. There were 41 cases of malignant tumors treated with LAK/IL-2CO (common LAK cells were 239 times), and 19 cases of side reactions occurred (the incidence was 7.9%). It is suggested that allogeneic LAK cells are safe and feasible. In the single-immunized group, 2 patients achieved PR, and the other 3 patients experienced improvement in symptoms. The effective rate of immunization with chemotherapy and radiotherapy was 54.1%. We believe that this therapy is a safe and effective method for the comprehensive treatment of malignant tumors. It is worth further investigation.